maki test

November 19, 2003 09:18 ET | Source: Basilea Pharmaceutica AG, Allschwil

For release content, please refer to the attachment.

Recommended Reading

March 23, 2026 02:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
Read More
February 25, 2026 01:15 ET | Source: Basilea Pharmaceutica International Ltd, Allschwil

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company...
Read More